Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa. , Aug.
This article is featured on another website.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.